CS MEDICA A/S Statement of Extraordinary General Meeting
Today on April 14, 2023, in Copenhagen – CS MEDICA A/S (”CS MEDICA” or “The Company”) held an extraordinary general meeting (“EGM”) at which the following principal resolutions were passed.
Approval of the first proposal to make a cash capital increase (direct issue) of 2,132,954 new shares at a price of DKK 28.13 per share.
The EGM resolved in accordance with the Board of Directors’ proposal to make a cash capital increase (direct issue) to be subscribed by Inner Mongolia RongShi Hi-Tech Co., Ltd.(“RongShi”) of 2,132,954 shares at a price of DKK 28.13 per share, without pre-emption right for the existing shareholders.
Approval of the second proposal authorizing the board of directors to issue 2,132,954 shares to RongShi.
The EGM resolved in accordance with the Board of Directors’ proposal to authorize the board of directors to issue the shares to RongShi under the described terms. The authorization is valid for a period of five years from the date of the extraordinary general meeting.
The total number of votes as of the date of this Statement is 12,322,635, whereof 66,2%, equal to 8.154,509, votes was represented at the EGM.
The resolutions were approved unanimously by all shareholders represented at the EGM.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). more information, visit cs-medica.com, and LinkedIn.